<p>Bio-Techne Corp (NASDAQ:TECH - 获取免费报告) 的股价在周三下跌了 10.8%，原因是其财报表现低于预期。该公司股价最低曾达到 49.77 美元，最后交易价为 50.5320 美元。在交易过程中，约有 2,041,218 股成交，较日均成交量 2,317,194 股下降了 12%。该股票此前收盘价为 56.68 美元。</p>
<ul>
<li>Bio-Techne、J2 Global 和 InMode 从底部突破，接近买入点</li>
</ul>
<p>这家生物技术公司报告本季度每股收益为 0.53 美元，低于市场共识预期的 0.55 美元，差距为 0.02 美元。该公司本季度的收入为 3.1142 亿美元，而分析师预期为 3.1608 亿美元。Bio-Techne 的净利润率为 6.67%，股本回报率为 13.94%。该公司的收入同比下降了 1.5%。在去年同期，该公司每股收益为 0.56 美元。</p>
<h2>华尔街分析师预测增长</h2>
<p>TECH 已成为多份研究分析报告的主题。Benchmark 在 2 月 3 日的研究报告中重申了对 Bio-Techne 股票的 “买入” 评级。富国银行在 2 月 6 日的研究报告中将 Bio-Techne 的目标价从 70.00 美元上调至 76.00 美元，并给予该股票 “超配” 评级。Zacks Research 在 2 月 9 日的报告中将 Bio-Techne 的评级从 “强烈卖出” 上调至 “持有”。Evercore 在 2 月 5 日的报告中将 Bio-Techne 的目标价从 62.00 美元上调至 68.00 美元，并给予该公司 “持平” 评级。最后，TD Cowen 在 3 月 17 日的报告中重申了对 Bio-Techne 股票的 “买入” 评级。一位投资分析师给予该股票 “强烈买入” 评级，九位给予 “买入” 评级，三位给予 “持有” 评级，一位给予 “卖出” 评级。根据 MarketBeat.com 的数据，Bio-Techne 目前的平均评级为 “适度买入”，共识目标价为 72.77 美元。</p>
<p><strong>阅读我们对 Bio-Techne 的最新分析</strong></p>
<h2>Bio-Techne 的机构交易</h2>
<p>几家对冲基金最近调整了对该股票的持有。Asset Management One Co. Ltd.在第四季度将其在 Bio-Techne 的持股增加了 2.7%。Asset Management One Co. Ltd.目前拥有 5,752 股该生物技术公司的股票，价值 341,000 美元，此前在上个季度增持了 153 股。Accredited Investors Inc.在第四季度将其在 Bio-Techne 的持股增加了 2.7%。Accredited Investors Inc.目前拥有 6,052 股该生物技术公司的股票，价值 356,000 美元，此前增持了 161 股。Allworth Financial LP 在第三季度将其在 Bio-Techne 的持股增加了 28.4%。Allworth Financial LP 目前拥有 786 股该生物技术公司的股票，价值 44,000 美元，此前增持了 174 股。Oppenheimer &amp; Co. Inc.在第四季度将其在 Bio-Techne 的持股增加了 3.5%。Oppenheimer &amp; Co. Inc.目前拥有 5,351 股该生物技术公司的股票，价值 315,000 美元，此前增持了 181 股。最后，Angeles Wealth Management LLC 在第三季度将其在 Bio-Techne 的持股增加了 3.4%。Angeles Wealth Management LLC 目前拥有 5,703 股该生物技术公司的股票，价值 317,000 美元，此前增持了 189 股。98.95% 的股票由机构投资者持有。</p>
<h2>Bio-Techne 股价下跌 10.6%</h2>
<p>该公司的市值为 79.2 亿美元，市盈率为 99.38，市盈增长比率为 3.60，贝塔值为 1.41。该公司的债务与股本比率为 0.13，速动比率为 3.08，流动比率为 4.54。该公司的 50 日移动平均线为 54.70 美元，200 日移动平均线为 59.71 美元。</p>
<h2>Bio-Techne 公司简介</h2>
<p>(获取免费报告)</p>
<p>Bio-Techne Corporation NASDAQ: TECH 是一家全球生命科学公司，开发、制造和销售高质量的试剂、仪器和服务，服务于研究、诊断和生物加工市场。其核心产品包括重组蛋白、抗体、免疫测定、核酸探针和试剂盒、单细胞分析解决方案以及自动化蛋白分析系统。旗舰品牌如 R&amp;D Systems、Novus Biologicals、ProteinSimple 和 Advanced Cell Diagnostics 为研究人员和临床医生提供可靠的细胞生物学、免疫学、蛋白质组学和基因组学应用工具。</p>
<p>Bio-Techne 总部位于明尼阿波利斯，明尼苏达州，通过直接销售、分销商和战略合作伙伴关系为北美、欧洲和亚太地区的客户提供服务。</p>
<h2>精选故事</h2>
<ul>
<li>我们更看好的五只股票超过 Bio-Techne</li>
</ul>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Bio-Techne 吗？</h2>
<p>在你考虑 Bio-Techne 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 Bio-Techne 并不在名单上。</p>
<p>虽然 Bio-Techne 目前在分析师中获得 “适度买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

TECH

<p>Bio-Techne Corp（纳斯达克代码：TECH）股价下跌 10.8%，至 50.53 美元，此前公司公布的财报令人失望，每股收益（EPS）低于预期 0.02 美元，营收低于预期 466 万美元。公司的营收同比下降 1.5%。分析师维持 “适度买入” 评级，目标价共识为 72.77 美元。机构投资者持有 98.95% 的股份。Bio-Techne 专注于生命科学产品，包括用于研究和诊断的试剂和仪器</p>

<p>Bio-Techne Corp (NASDAQ:TECH - Get Free Report)'s stock price dropped 10.8% on Wednesday following a weaker than expected earnings announcement. The company traded as low as $49.77 and last traded at $50.5320. Approximately 2,041,218 shares traded hands during trading, a decline of 12% from the average daily volume of 2,317,194 shares. The stock had previously closed at $56.68.</p>
<div class="lb-trans"><p>Bio-Techne Corp (NASDAQ:TECH - 获取免费报告) 的股价在周三下跌了 10.8%，原因是其财报表现低于预期。该公司股价最低曾达到 49.77 美元，最后交易价为 50.5320 美元。在交易过程中，约有 2,041,218 股成交，较日均成交量 2,317,194 股下降了 12%。该股票此前收盘价为 56.68 美元。</p>
</div><ul>
<li>Bio-Techne, J2 Global And InMode Break Out Of Bases, Near Buy Points</li>
</ul>
<div class="lb-trans"><ul>
<li>Bio-Techne、J2 Global 和 InMode 从底部突破，接近买入点</li>
</ul>
</div><p>The biotechnology company reported $0.53 earnings per share for the quarter, missing the consensus estimate of $0.55 by ($0.02). The business had revenue of $311.42 million for the quarter, compared to analyst estimates of $316.08 million. Bio-Techne had a net margin of 6.67% and a return on equity of 13.94%. The firm's revenue was down 1.5% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.56 earnings per share.</p>
<div class="lb-trans"><p>这家生物技术公司报告本季度每股收益为 0.53 美元，低于市场共识预期的 0.55 美元，差距为 0.02 美元。该公司本季度的收入为 3.1142 亿美元，而分析师预期为 3.1608 亿美元。Bio-Techne 的净利润率为 6.67%，股本回报率为 13.94%。该公司的收入同比下降了 1.5%。在去年同期，该公司每股收益为 0.56 美元。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><p>TECH has been the topic of several research analyst reports. Benchmark reiterated a &#34;buy&#34; rating on shares of Bio-Techne in a research report on Tuesday, February 3rd. Wells Fargo &amp; Company lifted their price objective on shares of Bio-Techne from $70.00 to $76.00 and gave the stock an &#34;overweight&#34; rating in a research report on Friday, February 6th. Zacks Research upgraded shares of Bio-Techne from a &#34;strong sell&#34; rating to a &#34;hold&#34; rating in a report on Monday, February 9th. Evercore boosted their price target on shares of Bio-Techne from $62.00 to $68.00 and gave the company an &#34;in-line&#34; rating in a report on Thursday, February 5th. Finally, TD Cowen restated a &#34;buy&#34; rating on shares of Bio-Techne in a report on Tuesday, March 17th. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, Bio-Techne currently has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $72.77.</p>
<div class="lb-trans"><p>TECH 已成为多份研究分析报告的主题。Benchmark 在 2 月 3 日的研究报告中重申了对 Bio-Techne 股票的 “买入” 评级。富国银行在 2 月 6 日的研究报告中将 Bio-Techne 的目标价从 70.00 美元上调至 76.00 美元，并给予该股票 “超配” 评级。Zacks Research 在 2 月 9 日的报告中将 Bio-Techne 的评级从 “强烈卖出” 上调至 “持有”。Evercore 在 2 月 5 日的报告中将 Bio-Techne 的目标价从 62.00 美元上调至 68.00 美元，并给予该公司 “持平” 评级。最后，TD Cowen 在 3 月 17 日的报告中重申了对 Bio-Techne 股票的 “买入” 评级。一位投资分析师给予该股票 “强烈买入” 评级，九位给予 “买入” 评级，三位给予 “持有” 评级，一位给予 “卖出” 评级。根据 MarketBeat.com 的数据，Bio-Techne 目前的平均评级为 “适度买入”，共识目标价为 72.77 美元。</p>
</div><p><strong>Read Our Latest Analysis on Bio-Techne</strong></p>
<div class="lb-trans"><p><strong>阅读我们对 Bio-Techne 的最新分析</strong></p>
</div><h2>Institutional Trading of Bio-Techne</h2>
<div class="lb-trans"><h2>Bio-Techne 的机构交易</h2>
</div><p>Several hedge funds have recently modified their holdings of the stock. Asset Management One Co. Ltd. boosted its stake in Bio-Techne by 2.7% in the fourth quarter. Asset Management One Co. Ltd. now owns 5,752 shares of the biotechnology company's stock valued at $341,000 after acquiring an additional 153 shares during the last quarter. Accredited Investors Inc. raised its holdings in shares of Bio-Techne by 2.7% during the fourth quarter. Accredited Investors Inc. now owns 6,052 shares of the biotechnology company's stock worth $356,000 after acquiring an additional 161 shares during the period. Allworth Financial LP increased its stake in Bio-Techne by 28.4% in the 3rd quarter. Allworth Financial LP now owns 786 shares of the biotechnology company's stock valued at $44,000 after buying an additional 174 shares during the last quarter. Oppenheimer &amp; Co. Inc. grew its position in shares of Bio-Techne by 3.5% in the 4th quarter. Oppenheimer &amp; Co. Inc. now owns 5,351 shares of the biotechnology company's stock valued at $315,000 after acquiring an additional 181 shares during the period. Finally, Angeles Wealth Management LLC lifted its holdings in Bio-Techne by 3.4% during the 3rd quarter. Angeles Wealth Management LLC now owns 5,703 shares of the biotechnology company's stock valued at $317,000 after purchasing an additional 189 shares during the last quarter. 98.95% of the stock is owned by institutional investors.</p>
<div class="lb-trans"><p>几家对冲基金最近调整了对该股票的持有。Asset Management One Co. Ltd.在第四季度将其在 Bio-Techne 的持股增加了 2.7%。Asset Management One Co. Ltd.目前拥有 5,752 股该生物技术公司的股票，价值 341,000 美元，此前在上个季度增持了 153 股。Accredited Investors Inc.在第四季度将其在 Bio-Techne 的持股增加了 2.7%。Accredited Investors Inc.目前拥有 6,052 股该生物技术公司的股票，价值 356,000 美元，此前增持了 161 股。Allworth Financial LP 在第三季度将其在 Bio-Techne 的持股增加了 28.4%。Allworth Financial LP 目前拥有 786 股该生物技术公司的股票，价值 44,000 美元，此前增持了 174 股。Oppenheimer &amp; Co. Inc.在第四季度将其在 Bio-Techne 的持股增加了 3.5%。Oppenheimer &amp; Co. Inc.目前拥有 5,351 股该生物技术公司的股票，价值 315,000 美元，此前增持了 181 股。最后，Angeles Wealth Management LLC 在第三季度将其在 Bio-Techne 的持股增加了 3.4%。Angeles Wealth Management LLC 目前拥有 5,703 股该生物技术公司的股票，价值 317,000 美元，此前增持了 189 股。98.95% 的股票由机构投资者持有。</p>
</div><h2>Bio-Techne Stock Down 10.6%</h2>
<div class="lb-trans"><h2>Bio-Techne 股价下跌 10.6%</h2>
</div><p>The firm has a market cap of $7.92 billion, a P/E ratio of 99.38, a P/E/G ratio of 3.60 and a beta of 1.41. The company has a debt-to-equity ratio of 0.13, a quick ratio of 3.08 and a current ratio of 4.54. The firm's fifty day moving average is $54.70 and its 200 day moving average is $59.71.</p>
<div class="lb-trans"><p>该公司的市值为 79.2 亿美元，市盈率为 99.38，市盈增长比率为 3.60，贝塔值为 1.41。该公司的债务与股本比率为 0.13，速动比率为 3.08，流动比率为 4.54。该公司的 50 日移动平均线为 54.70 美元，200 日移动平均线为 59.71 美元。</p>
</div><h2>Bio-Techne Company Profile</h2>
<div class="lb-trans"><h2>Bio-Techne 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(获取免费报告)</p>
</div><p>Bio-Techne Corporation NASDAQ: TECH is a global life sciences company that develops, manufactures and sells high-quality reagents, instruments and services for the research, diagnostic and bioprocessing markets. Its core product offerings include recombinant proteins, antibodies, immunoassays, nucleic acid probes and kits, single-cell analysis solutions and automated protein analysis systems. Flagship brands such as R&amp;D Systems, Novus Biologicals, ProteinSimple and Advanced Cell Diagnostics provide researchers and clinicians with reliable tools for cell biology, immunology, proteomics and genomics applications.</p>
<div class="lb-trans"><p>Bio-Techne Corporation NASDAQ: TECH 是一家全球生命科学公司，开发、制造和销售高质量的试剂、仪器和服务，服务于研究、诊断和生物加工市场。其核心产品包括重组蛋白、抗体、免疫测定、核酸探针和试剂盒、单细胞分析解决方案以及自动化蛋白分析系统。旗舰品牌如 R&amp;D Systems、Novus Biologicals、ProteinSimple 和 Advanced Cell Diagnostics 为研究人员和临床医生提供可靠的细胞生物学、免疫学、蛋白质组学和基因组学应用工具。</p>
</div><p>Headquartered in Minneapolis, Minnesota, Bio-Techne serves customers across North America, Europe and the Asia-Pacific region through a combination of direct sales, distributors and strategic partnerships.</p>
<div class="lb-trans"><p>Bio-Techne 总部位于明尼阿波利斯，明尼苏达州，通过直接销售、分销商和战略合作伙伴关系为北美、欧洲和亚太地区的客户提供服务。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than Bio-Techne</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票超过 Bio-Techne</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Bio-Techne Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Bio-Techne 吗？</h2>
</div><p>Before you consider Bio-Techne, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Bio-Techne 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bio-Techne wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 Bio-Techne 并不在名单上。</p>
</div><p>While Bio-Techne currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Bio-Techne 目前在分析师中获得 “适度买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Bio-Techne (NASDAQ:TECH) 股价因业绩不佳下跌 10.8%